Now Is A Good Time To Buy Coherus Biosciences Inc (NASDAQ: CHRS)

During the last session, Coherus Biosciences Inc (NASDAQ:CHRS)’s traded shares were 2.21 million, with the beta value of the company hitting 0.55. At the end of the trading day, the stock’s price was $1.93, reflecting an intraday loss of -4.46% or -$0.09. The 52-week high for the CHRS share is $8.22, that puts it down -325.91 from that peak though still a striking 25.91% gain since the share price plummeted to a 52-week low of $1.43. The company’s market capitalization is $219.05M, and the average trade volume was 2.72 million shares over the past three months.

Coherus Biosciences Inc (NASDAQ:CHRS) trade information

Coherus Biosciences Inc (CHRS) registered a -4.46% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.46% in intraday trading to $1.93, hitting a weekly high. The stock’s 5-day price performance is -3.50%, and it has moved by -16.09% in 30 days. Based on these gigs, the overall price performance for the year is -75.19%.

Coherus Biosciences Inc (CHRS) estimates and forecasts

Statistics show that Coherus Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Coherus Biosciences Inc (CHRS) shares have gone down -40.98% during the last six months, with a year-to-date growth rate more than the industry average at 100.51% against 12.90. In the rating firms’ projections, revenue will increase 1.70% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 81.7M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 53.68M by the end of current fiscal year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 4.73%. While earnings are projected to return 77.42% in 2024.

CHRS Dividends

Coherus Biosciences Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders